Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Efficacy of PD-1 Inhibitors Combined with Anti-Angiogenic Therapy in Driver Gene Mutation Negative Non-Small-Cell Lung Cancer with Brain Metastases.

Discovery medicine - 1 Jun 2023

Song Jia-Qi, Wang Xia, Zeng Zhi-Min, Liang Ping-An, Zhong Cong-Ying, Liu An-Wen

Abstract excerpt

OBJECTIVE: Anti-angiogenic therapy has proven effective in non-small-cell lung cancer (NSCLC) patients. The purpose of this study was to evaluate the efficacy of programmed cell death protein 1 (PD-1) inhibitors combined with anti-angiogenic therapy in patients with driver gene mutation negative NSCLC and brain metastases (BMs). METHODS: A retrospective analysis was performed on NSCLC BMs in patients without...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Brain Neoplasms
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immune Checkpoint Inhibitors

Share to Lung Neoplasms

Share to Mutation

Source

Identifiers

PMID: 37272099
DOI: 10.24976/Discov.Med.202335176.33

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Efficacy of PD-1 Inhibitors Combined with Anti-Angiogenic Therapy in Driver Gene Mutation Negative Non-Small-Cell Lung Cancer with Brain Metastases.PMID 37272099Read ↗

Breaking Down Combination Strategies: PD-1/PD-L1 Inhibitors with Chemotherapy, Anti- Angiogenesis, or Both in Driver Gene-Negative NSCLC Clinical Outcomes and Mechanistic InsightsSemantic proximity Read ↗

Clinical efficacy and prognosis analysis of treatment regimens for EGFR mutant non-small cell lung cancer and brain metastasis: a retrospective study.Semantic proximity Read ↗

Management and Outcomes of Newly Diagnosed Non-Small Cell Lung Cancer Patients with Brain Metastases: A Real-World Study in Japan.Semantic proximity Read ↗

Greater efficacy of chemotherapy plus bevacizumab compared to chemo- and targeted therapy alone on non-small cell lung cancer patients with brain metastasis.Semantic proximity Read ↗

Therapeutic perspectives for brain metastases in non-oncogene addicted non-small cell lung cancer (NSCLC): Towards a less dismal future?Semantic proximity Read ↗

Concurrent Apatinib and Brain Radiotherapy in Patients With Brain Metastases From Driver Mutation-negative Non-small-cell Lung Cancer: Study Protocol for an Open-label Randomized Controlled Trial.Semantic proximity Read ↗

Treatment outcomes and prognostic factors in patients with driver mutant non-small cell lung cancer and de novo brain metastasesSemantic proximity Read ↗

A study on different therapies and prognosis-related factors for brain metastases in lung adenocarcinoma patients with driver mutation.Semantic proximity Read ↗

The Efficacy of First-Generation EGFR-TKI Combined With Brain Radiotherapy as the First-Line Treatment for Lung Adenocarcinoma Patients With Brain Metastases and EGFR Sensitive Mutations: A Retrospective study.Semantic proximity Read ↗

[Targeted Therapies for Driver Gene Mutation-positive Lung Cancer Patients with Brain Metastasis].Semantic proximity Read ↗

A retrospective study of the efficacy and safety of Almonertinib in the treatment of locally advanced or brain metastatic non-small cell lung cancer with EGFR-positive mutationsSemantic proximity Read ↗

EGFR-TKI monotherapy versus combination therapy as first-line treatment for EGFR-mutant NSCLC with brain metastases: a real-world comparison analysis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.